▶ 調査レポート

神経障害性疼痛治療の世界市場2020-2030:薬物クラス別(抗けいれん薬、抗うつ薬、NSAID、オピオイド、ステロイド、その他)、投与経路別、疾患別、流通チャンネル別

• 英文タイトル:Neuropathic Pain Therapeutics Market (Drug Class: Anticonvulsants, Antidepressants, NSAIDs, Opioids, Steroids, and Others; Indication: Diabetic Neuropathy, Post-herpetic Neuralgia, Cancer-related Pain, Spinal Cord Injury, and Others; Route of Administration: Oral, Topical, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Transparency Market Researchが調査・発行した産業分析レポートです。神経障害性疼痛治療の世界市場2020-2030:薬物クラス別(抗けいれん薬、抗うつ薬、NSAID、オピオイド、ステロイド、その他)、投与経路別、疾患別、流通チャンネル別 / Neuropathic Pain Therapeutics Market (Drug Class: Anticonvulsants, Antidepressants, NSAIDs, Opioids, Steroids, and Others; Indication: Diabetic Neuropathy, Post-herpetic Neuralgia, Cancer-related Pain, Spinal Cord Injury, and Others; Route of Administration: Oral, Topical, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030 / TMR2008084資料のイメージです。• レポートコード:TMR2008084
• 出版社/出版日:Transparency Market Research / 2020年6月
• レポート形態:英文、PDF、238ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥764,940 (USD5,795)▷ お問い合わせ
  Multi User¥1,160,940 (USD8,795)▷ お問い合わせ
  Corporate License¥1,556,940 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは神経障害性疼痛治療の世界市場について調査・分析し、序文、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、薬物クラス別(抗けいれん薬、抗うつ薬、NSAID、オピオイド、ステロイド)分析、疾患別(糖尿病性神経障害、帯状疱疹後神経痛、がん関連痛み、脊髄損傷、その他)分析、投与経路別(経口、局所、その他)分析、流通チャンネル別(病院薬局、小売薬局、オンライン薬局)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などを含め、以下の構成でご提供いたします。
・序文
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・市場見通し
・神経障害性疼痛治療の世界市場:薬物クラス別(抗けいれん薬、抗うつ薬、NSAID、オピオイド、ステロイド)
・神経障害性疼痛治療の世界市場:疾患別(糖尿病性神経障害、帯状疱疹後神経痛、がん関連痛み、脊髄損傷、その他)
・神経障害性疼痛治療の世界市場:投与経路別(経口、局所、その他)
・神経障害性疼痛治療の世界市場:流通チャンネル別(病院薬局、小売薬局、オンライン薬局)
・神経障害性疼痛治療の世界市場:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況

Neuropathic Pain Therapeutics Market – Scope of the Report

TMR’s report on the global neuropathic pain therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the revenue of the global neuropathic pain therapeutics market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global neuropathic pain therapeutics market from 2020 to 2030.

The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global neuropathic pain therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global neuropathic pain therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global neuropathic pain therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global neuropathic pain therapeutics market.

The report also delves into the competition landscape of the global neuropathic pain therapeutics market. Key players operating in the global neuropathic pain therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global neuropathic pain therapeutics market that have been profiled in this report.

Key Questions Answered in Neuropathic Pain Therapeutics Market Report

What is the sales/revenue generated by neuropathic pain drugs across all regions during the forecast period?
What are the opportunities in the global neuropathic therapeutics pain market?
What are the major drivers, restraints, opportunities, and threats in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which indication segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Neuropathic Pain Therapeutics Market – Research Objectives and Research Approach

The comprehensive report on the global neuropathic pain therapeutics market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global neuropathic pain therapeutics market in terms of drug class, disease type, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2030 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global neuropathic pain therapeutics market.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neuropathic Pain Therapeutics Market

4. Market Overview

4.1. Introduction & Overview

4.2. Product Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, 2018–2030

5. Market Outlook

5.1. Pipeline Analysis

5.2. Treatment Guidelines

5.3. COVID-19 Pandemics Impact on Industry

6. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

6.2.1. Anticonvulsants

6.2.2. Antidepressants

6.2.2.1. Tricyclic Antidepressants

6.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

6.2.3. NSAIDs

6.2.4. Opioids

6.2.5. Steroids

6.2.6. Others

6.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class

7. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Indication

7.1. Introduction & Definition

7.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Indication, 2018–2030

7.2.1. Diabetic Neuropathy

7.2.2. Post-herpetic Neuralgia

7.2.3. Cancer-related Pain

7.2.4. Spinal Cord Injury

7.2.5. Others

7.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication

8. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Route of Administration

8.1. Introduction & Definition

8.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Route of Administration, 2018–2030

8.2.1. Oral

8.2.2. Topical

8.2.3. Others

8.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration

9. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Distribution Channel

9.1. Introduction & Definition

9.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

9.2.1. Hospital Pharmacies

9.2.2. Retail Pharmacies

9.2.3. Online Pharmacies

9.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel

10. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Region

10.1. Key Findings

10.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region

10.2.1. North America

10.2.2. Europe

10.2.3. Asia Pacific

10.2.4. Latin America

10.2.5. Middle East & Africa

10.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region

11. North America Neuropathic Pain Therapeutics Market Analysis and Forecast

11.1. Introduction

11.2. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

11.2.1. Anticonvulsants

11.2.2. Antidepressants

11.2.2.1. Tricyclic Antidepressants

11.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

11.2.3. NSAIDs

11.2.4. Opioids

11.2.5. Steroids

11.2.6. Others

11.3. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

11.3.1. Diabetic Neuropathy

11.3.2. Post-herpetic Neuralgia

11.3.3. Cancer-related Pain

11.3.4. Spinal Cord Injury

11.3.5. Others

11.4. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

11.4.1. Oral

11.4.2. Topical

11.4.3. Others

11.5. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

11.5.1. Hospital Pharmacies

11.5.2. Retail Pharmacies

11.5.3. Online Pharmacies

11.6. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

11.6.1. U.S.

11.6.2. Canada

11.7. North America Neuropathic Pain Therapeutics Market Attractiveness Analysis

11.7.1. By Drug Class

11.7.2. By Indication

11.7.3. By Route of Administration

11.7.4. By Distribution Channel

11.7.5. By Country

12. Europe Neuropathic Pain Therapeutics Market Analysis and Forecast

12.1. Introduction

12.2. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

12.2.1. Anticonvulsants

12.2.2. Antidepressants

12.2.2.1. Tricyclic Antidepressants

12.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

12.2.3. NSAIDs

12.2.4. Opioids

12.2.5. Steroids

12.2.6. Others

12.3. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

12.3.1. Diabetic Neuropathy

12.3.2. Post-herpetic Neuralgia

12.3.3. Cancer-related Pain

12.3.4. Spinal Cord Injury

12.3.5. Others

12.4. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

12.4.1. Oral

12.4.2. Topical

12.4.3. Others

12.5. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

12.5.1. Hospital Pharmacies

12.5.2. Retail Pharmacies

12.5.3. Online Pharmacies

12.6. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

12.6.1. Germany

12.6.2. U.K.

12.6.3. France

12.6.4. Spain

12.6.5. Italy

12.6.6. Rest of Europe

12.7. Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis

12.7.1. By Drug Class

12.7.2. By Indication

12.7.3. By Route of Administration

12.7.4. By Distribution Channel

12.7.5. By Country/Sub-region

13. Asia Pacific Neuropathic Pain Therapeutics Market Analysis and Forecast

13.1. Introduction

13.2. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

13.2.1. Anticonvulsants

13.2.2. Antidepressants

13.2.2.1. Tricyclic Antidepressants

13.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

13.2.3. NSAIDs

13.2.4. Opioids

13.2.5. Steroids

13.2.6. Others

13.3. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

13.3.1. Diabetic Neuropathy

13.3.2. Post-herpetic Neuralgia

13.3.3. Cancer-related Pain

13.3.4. Spinal Cord Injury

13.3.5. Others

13.4. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

13.4.1. Oral

13.4.2. Topical

13.4.3. Others

13.5. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

13.5.1. Hospital Pharmacies

13.5.2. Retail Pharmacies

13.5.3. Online Pharmacies

13.6. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

13.6.1. China

13.6.2. Japan

13.6.3. India

13.6.4. Australia & New Zealand

13.6.5. Rest of Asia Pacific

13.7. Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis

13.7.1. By Drug Class

13.7.2. By Indication

13.7.3. By Route of Administration

13.7.4. By Distribution Channel

13.7.5. By Country/Sub-region

14. Latin America Neuropathic Pain Therapeutics Market Analysis and Forecast

14.1. Introduction

14.2. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

14.2.1. Anticonvulsants

14.2.2. Antidepressants

14.2.2.1. Tricyclic Antidepressants

14.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

14.2.3. NSAIDs

14.2.4. Opioids

14.2.5. Steroids

14.2.6. Others

14.3. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

14.3.1. Diabetic Neuropathy

14.3.2. Post-herpetic Neuralgia

14.3.3. Cancer-related Pain

14.3.4. Spinal Cord Injury

14.3.5. Others

14.4. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

14.4.1. Oral

14.4.2. Topical

14.4.3. Others

14.5. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

14.5.1. Hospital Pharmacies

14.5.2. Retail Pharmacies

14.5.3. Online Pharmacies

14.6. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

14.6.1. Brazil

14.6.2. Mexico

14.6.3. Rest of Latin America

14.7. Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis

14.7.1. By Drug Class

14.7.2. By Indication

14.7.3. By Route of Administration

14.7.4. By Distribution Channel

14.7.5. By Country/Sub-region

15. Middle East & Africa Neuropathic Pain Therapeutics Market Analysis and Forecast

15.1. Introduction

15.2. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

15.2.1. Anticonvulsants

15.2.2. Antidepressants

15.2.2.1. Tricyclic Antidepressants

15.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)

15.2.3. NSAIDs

15.2.4. Opioids

15.2.5. Steroids

15.2.6. Others

15.3. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

15.3.1. Diabetic Neuropathy

15.3.2. Post-herpetic Neuralgia

15.3.3. Cancer-related Pain

15.3.4. Spinal Cord Injury

15.3.5. Others

15.4. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

15.4.1. Oral

15.4.2. Topical

15.4.3. Others

15.5. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

15.5.1. Hospital Pharmacies

15.5.2. Retail Pharmacies

15.5.3. Online Pharmacies

15.6. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

15.6.1. GCC Countries

15.6.2. South Africa

15.6.3. Rest of Middle East & Africa

15.7. Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis

15.7.1. By Drug Class

15.7.2. By Indication

15.7.3. By Route of Administration

15.7.4. By Distribution Channel

15.7.5. By Country/Sub-region

16. Competition Landscape

16.1. Competition Matrix

16.2. Market Share Analysis, by Company, 2019

16.3. Company Profiles

16.3.1. Novartis AG

16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.1.2. Company Financials

16.3.1.3. Growth Strategies

16.3.1.4. SWOT Analysis

16.3.2. GlaxoSmithKline plc

16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.2.2. Company Financials

16.3.2.3. Growth Strategies

16.3.2.4. SWOT Analysis

16.3.3. AstraZeneca

16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.3.2. Company Financials

16.3.3.3. Growth Strategies

16.3.3.4. SWOT Analysis

16.3.4. Pfizer, Inc.

16.3.4.1. Company Overview (HQ, Business Segments)

16.3.4.2. Company Financials

16.3.4.3. Growth Strategies

16.3.4.4. SWOT Analysis

16.3.5. Eli Lilly and Company

16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.5.2. Company Financials

16.3.5.3. Growth Strategies

16.3.5.4. SWOT Analysis

16.3.6. Mallinckrodt Pharmaceuticals

16.3.6.1. Company Overview (HQ, Business Segments)

16.3.6.2. Company Financials

16.3.6.3. Growth Strategies

16.3.6.4. SWOT Analysis

16.3.7. Johnson & Johnson

16.3.7.1. Company Overview (HQ, Business Segments)

16.3.7.2. Company Financials

16.3.7.3. Growth Strategies

16.3.7.4. SWOT Analysis

16.3.8. Abbott

16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.8.2. Company Financials

16.3.8.3. Growth Strategies

16.3.8.4. SWOT Analysis

16.3.9. Endo Pharmaceuticals, Inc.

16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.9.2. Company Financials

16.3.9.3. Growth Strategies

16.3.9.4. SWOT Analysis

16.3.10. Teva Pharmaceutical Industries Limited

16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.10.2. Company Financials

16.3.10.3. Growth Strategies

16.3.10.4. SWOT Analysis

16.3.11. Merck & Co., Inc.

16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.11.2. Company Financials

16.3.11.3. Growth Strategies

16.3.11.4. SWOT Analysis

List of Tables

Table 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 03: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 04: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 05: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 08: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 09: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 10: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 11: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 12: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 13: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 14: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 15: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 16: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 18: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 19: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 20: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 21: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 22: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 23: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 24: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 25: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 26: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 27: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 28: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 29: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 30: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 31: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 32: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030

Table 33: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 34: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 35: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 36: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030